Pressemitteilung BoxID: 337954 (ALRISE Biosystems GmbH)
  • ALRISE Biosystems GmbH
  • Robert-Roessle-Straße 10
  • 13125 Berlin
  • Ansprechpartner
  • Celal Albayrak
  • +49 (30) 94892483

ALRISE Wins Dr. Alessandro Banchi to Join its Advisory Board

(PresseBox) (Berlin, ) ALRISE Biosystems GmbH, the Berlinbased drug delivery specialist, announced that with Dr. Alessandro Banchi it has won yet another topclass Pharma industry expert for its Advisory Board.

"We are excited and proud that we were able to complete our already excellent Advisory Board," stated Dr. Celal Albayrak, CEO and founder of ALRISE. "As the longstanding Chairman of the Board of Managing Directors of Boehringer Ingelheim, one of the world's leading pharmaceutical companies, Dr. Banchi brings with him an exceptional reputation and extensive experience to support ALRISE in further establishing itself as a preferred pharmaceutical industry partner in the market for 'controlledrelease' formulations."

Other members of the Advisory Board are Prof. em. Dr. Hans P. Merkle, professor emeritus at the Institute of Pharmaceutical Sciences of the ETH Zurich (Switzerland) and one of the most renowned scientists in the area of parenteral depot dosage forms, as well as Dr. Giuseppe Vita, longstanding CEO of Schering AG and member of the Supervisory Board of several international publiclytraded companies. Dr. Vita, who already became a private shareholder of Alrise in 2008, will still be heading the Advisory Board.

ALRISE possesses a highly innovative and worldwide patented technology platform with outstanding and unique attributes. In addition to its use for new formulations of active pharmaceutical ingredients, the ImSus® technology in particular answers the current demand in the pharmaceutical industry for product lifecycle management as well as for supergeneric products.

Micro particle depot formulations, ALRISE's core business, dramatically reduce the dosing frequency and achieve a steady pharmacokinetic profile for better tolerability, reduced side effects, and improved patient compliance. In contrast to the competing methods, ImSus® technology only uses nontoxic solvents. This leads to an improved product safety profile as well as a more straightforward and faster approval process. In addition, the ImSus® technology is well suited for the formulation of biologicals such as proteins and peptides as well as small hydrophobic molecules as it considerably improves bioavailability through microencapsulation.

About IBB Beteiligungsgesellschaft mbH und VC Fonds Berlin GmbH:

IBB Beteiligungsgesellschaft ( provides equity financing to innovative Berlinbased companies. The firm is the regional market leader in venture capital in Berlin. IBB Beteiligungsgesellschaft was founded in 1997 as a fully owned subsidiary of Investitionsbank Berlin (IBB). The funds provided are to be used for the development and launch of innovative products and services. IBB Beteiligungsgesellschaft manages the "VC Fonds Technologie Berlin" fund (€ 52M) and the "VC Fonds Kreativwirtschaft Berlin" fund (€ 30M). Both funds were started as joint initiatives of IBB and the State of Berlin. They are cofinanced by the European Regional Development Fund (ERDF). Since 1997 the IBB Beteiligungsgesellschaft, in consortia with partners, has placed over € 650M at the disposal of technology and creative firms in Berlin. Of this, an amount of € 83M was invested by the IBB as lead, colead or coinvestor.


Creathor Venture invests in technologyoriented companies and entrepreneurs in the areas of life science, IT, telecommunication, new media, new materials, electronics, nanotechnology and clean tech. Creathor Venture's management team includes Dr. Gert Köhler, the founder of the former Technologieholding VC GmbH, as well as Ingo Franz and Karlheinz Schmelig. The team has been working in earlystage venture capital for 20 years. During that time more than 200 technology companies have been financed and over 20 IPOs as well as numerous trade sales have been conducted. Successful portfolio companies in the field of life sciences are Accovion, SiRION Biotech, Caprotec Bioanalytics, Phenex Pharmaceuticals and CEVEC Pharmaceuticals.

ALRISE Biosystems GmbH

ALRISE Biosystems GmbH ( was founded in January 2004 by Dr. Celal Albayrak together with Dr. Volker Rindler and Dr. Heiko Seemann. In January 2006, the company closed its first round of financing for € 1.5M with CREATHOR VENTURE and IBB Beteiligungsgesellschaft mbH. In July 2008 Dr. Giuseppe Vita joined the company as private shareholder via capital increase. In collaboration with large pharmaceutical and biotechnology companies ALRISE develops controlledrelease formulations for various substance classes. ALRISE is expecting to launch its first product in Germany within the next two to three years.